Background IGV-001 is a personalized, autologous cancer cell-based immunotherapy conceived to deliver a tumor-derived antigenic payload in the context of immunostimulatory signals to patients with glioblastoma (GBM). IGV-001 consists of patient-derived GBM cells treated with an antisense oligodeoxynucleotide against insulin-like growth factor 1 receptor (IGF1R) and placed in proprietary biodiffusion chambers (BDCs). The BDCs are… Continue reading A biologic-device combination product delivering tumor-derived antigens elicits immunogenic cell death-associated immune responses against glioblastoma
Tag: Skin Cancer
Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck
Phase I study investigating definitive radioimmunotherapy (RIT) with nivolumab and ipilimumab for the treatment of locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN) The primary endpoint was safety of definitive RIT . Secondary endpoints included progression-free survival (PFS) and overall survival . 5 individuals developed in-field soft tissue ulceration during consolidation… Continue reading Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck
Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis
The TLPLDC vaccine is made by ex vivo priming matured autologous dendritic cells with yeast cell wall particles (YCWPs) loaded with tumor lysate, particle only (TLPO) vaccine . Patients receiving the TLPO vaccine were further divided by their method of DC harvest (with or without G-CSF pretreatment), this was not randomized . Safety was assessed… Continue reading Prospective, randomized, double-blind phase 2B trial of the TLPO and TLPLDC vaccines to prevent recurrence of resected stage III/IV melanoma: a prespecified 36-month analysis
Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review
Immune-related adverse events (irAEs) are toxicities resulting from use of immune checkpoint inhibitors (ICIs) These side effects persist in some patients despite withholding therapy and using immunosuppressive and immune-modulating agents . The most common ICIs delivered were pembrolizumab (24%) and nivolumabs (37%) Most patients (75%) had metastatic disease and the primary cancer site was melanoma… Continue reading Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review
AACR-AHNS Head and Neck Cancer Conference: Highlights from the Cutting Edge
Across the surfaces of your mouth, throat, and nasal sinuses, layers of flat cells called squamous cells protect the underlying tissues from injury and pathogens. While these guardian cells are crucial to preserve the function of the tissues they defend, factors such as aging, tobacco, environmental pollutants, and infections can damage the squamous cells, potentially… Continue reading AACR-AHNS Head and Neck Cancer Conference: Highlights from the Cutting Edge
Novel RNA-based Therapy Targets Melanoma
Cancer is a general term that encompasses different subtypes of abnormal cellular growth in different areas of the body. One such type of cancer is the uncontrollable proliferation of skin cells known as melanoma. Melanoma can be metastatic, meaning it can spread to other areas of the body. It can also form in the eye… Continue reading Novel RNA-based Therapy Targets Melanoma
Opdivo Improves Disease-Free Survival in Skin Cancer Subtype
Patients with advanced Merkel cell carcinoma treated with Opdivo had improved disease-free survival rates compared with those who underwent observation.
Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia
Only limited efficacy of chimeric antigen receptor T (CAR-T) cell therapy is observed in acute myeloid leukaemia (AML) patients . CD123 and CLL-1 were highly expressed on AML cells . The proportions of T cell subsets and NK cells involved in anti-tumour processes in patients significantly decreased when compared with healthy donors . A possible… Continue reading Valproic acid increases CAR T cell cytotoxicity against acute myeloid leukemia
From the Bench: Creative Approaches in Cancer Research
Improved patient outcomes come from new treatments. New treatments stem from successful clinical trials. Clinical trials build on discoveries made in the lab. And laboratory discoveries? Those rely on a vast array of assays and specialized technologies, combined with the ingenuity of bench scientists who devise, master, and apply these tools in creative ways to… Continue reading From the Bench: Creative Approaches in Cancer Research
Utility of CYP2D6 copy number variants as prognostic biomarker in localized anal squamous cell carcinoma
Copy number variants (CNVs) were identified and their relation to disease-free survival (DFS) was studied and validated in an independent cohort of 101 ASCC patients from the Multidisciplinary Spanish Digestive Cancer Group . Mitochondria and mitochondrial cell-cycle proteins were overexpressed in patients with CYP2D6 CNV . This study may be useful to suggest new treatment strategies… Continue reading Utility of CYP2D6 copy number variants as prognostic biomarker in localized anal squamous cell carcinoma